Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A.
The immunoreactivity of PNL2 and antityrosinase in formalin-fixed, paraffin-embedded canine melanocytic neoplasms (n = 101) was compared with that of Melan A. Of the 113 samples overall, 106 were positive for PNL2, 101 for Melan A, and 90 for tyrosinase. Six melanomas that were positive for PNL2 were negative for Melan A; 1 melanoma that was negative for PNL2 was positive for Melan A. Eighty tumors were positive for all 3 markers; 111 reacted with at least 1 the 3 antibodies. Decalcification with formic acid for up to 1 week did not affect immunoreactivity of any of the markers; however, decalcification with HCl for 1 day or 1 week notably decreased or completely abrogated immunoreactivity for Melan A and PNL2. There was only minor loss of immunoreactivity for tyrosinase in tissues decalcified with HCl for 1 week. Prolonged fixation (up to 2 months) did not affect PNL2 or tyrosinase immunoreactivity; however, Melan A immunoreactivity was reduced after 1 month of fixation. PNL2 was not expressed in 120 nonmelanocytic tumors (carcinomas, sarcomas, steroid-producing tumors, and leukocytic tumors). In summary, antibody PNL2 is slightly more sensitive than Melan A and more sensitive than tyrosinase in the identification of canine melanocytic neoplasms. Furthermore, PNL2 does not appear to cross-react with nonmelanocytic neoplasms. PNL2 is resistant to prolonged fixation but sensitive to strong decalcification. Results indicate that PNL2 is an excellent marker in the identification of canine melanomas and that the sensitivity is close to 100% when used in conjunction with Melan A and tyrosinase.
Ramos-Vara
J A
JA
Department of Comparative Pathbiology, Purdue University, West Lafayette, IN 47907, USA. ramosja@purdue.edu
Miller
M A
MA
D000818:Animals; D000906:Antibodies; D014408:Biomarkers, Tumor / Q000276:immunology; D004283:Dog Diseases / Q000175:diagnosis* / Q000473:pathology*; D004285:Dogs; D007150:Immunohistochemistry / Q000662:veterinary; D008545:Melanoma / Q000175:diagnosis / Q000473:pathology / Q000662:veterinary*; D058950:Melanoma-Specific Antigens / Q000276:immunology*; D014442:Monophenol Monooxygenase / Q000276:immunology*
D000906:Antibodies; D014408:Biomarkers, Tumor; D058950:Melanoma-Specific Antigens; D014442:Monophenol Monooxygenase